Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426047 | 0.88 | KMT2A (0.51) | KEAP1SMN1; SMN2KMT2AMEN1HRH3 | |
| SCHEMBL4342856 | 0.83 | KEAP1 (0.54) | KEAP1SMN1; SMN2KMT2AMEN1EPHX2 | |
| SCHEMBL2411125 | 0.82 | KEAP1 (0.52) | KEAP1SMN1; SMN2KMT2AMEN1EPHX2 | |
| SCHEMBL15732 | 0.82 | KEAP1 (0.52) | KEAP1SMN1; SMN2KMT2AMEN1EPHX2 | |
| SCHEMBL3219498 | 0.81 | HRH3 (0.48) | SMN1; SMN2HRH3MAPTALDH1A1POLB | |
| SCHEMBL25942368 | 0.81 | KEAP1 (0.47) | KEAP1SMN1; SMN2KMT2AMEN1EPHX2 | |
| SCHEMBL13851213 | 0.80 | KEAP1 (0.50) | KEAP1SMN1; SMN2KMT2AMEN1EPHX2 | |
| SCHEMBL161681 | 0.80 | KEAP1 (0.50) | KEAP1SMN1; SMN2KMT2AMEN1EPHX2 | |
| Hydrochloric Acid SCHEMBL31040251 | 0.80 | GLA (0.50) | KEAP1SMN1; SMN2KMT2AMEN1EPHX2 | |
| SCHEMBL4022655 | 0.80 | KEAP1 (0.50) | KEAP1SMN1; SMN2KMT2AMEN1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492536-B1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-09 | — | — | EP | claimed |
| US-20090306126-A1 | Indole Derivatives | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | claimed |
| US-20090118336-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | claimed |
| EP-2029593-A1 | INDOLE DERIVATIVES | AstraZeneca AB (SE) | 2009-03-04 | — | — | EP | claimed |
| EP-2016068-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | AstraZeneca AB (SE) | 2009-01-21 | — | — | EP | claimed |
| WO-2007135398-A1 | INDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | claimed |
| WO-2007129052-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| US-7119084-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-10 | — | — | US | claimed |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | claimed |
| US-6924285-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2005-08-02 | — | — | US | claimed |
| EP-1492536-A1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-01-05 | — | — | EP | claimed |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | claimed |
| WO-2003082290-A1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-09 | — | — | WO | claimed |
| EP-1606268-B1 | 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS | ABBVIE INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-8343982-B2 | Bicyclic heterocyclic compounds pharmaceutical compositions containing these compounds, their use and process for preparing the same | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-20110077246-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THE SAME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2011-03-31 | — | — | US | disclosed |
| US-20040254159-A1 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES | 2004-12-16 | — | — | US | disclosed |
| WO-2004076424-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-10 | — | — | WO | disclosed |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | disclosed |
| WO-2003082290-A1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254159-A1 | Heterocyclic kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | KEAP1 747/4885SMN1; SMN2 3469/4885KMT2A 1398/4885 |
| US-20110077246-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THE SAME | CYP11B2, CYP11B1, PKD1 | KEAP1 202/4885SMN1; SMN2 2512/4885KMT2A 4155/4885 |
| US-20090306126-A1 | Indole Derivatives | MTOR, IDO1, AKT1S1 | KEAP1 1332/4885SMN1; SMN2 3364/4885KMT2A 1906/4885 |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B2, CYP11B1, HPGD | KEAP1 206/4885SMN1; SMN2 2655/4885KMT2A 4215/4885 |
| US-20090118336-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MTOR, RICTOR, PIK3R5 | KEAP1 2625/4885SMN1; SMN2 4121/4885KMT2A 3091/4885 |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B1, AR, CYP11B2 | KEAP1 1011/4885SMN1; SMN2 4567/4885KMT2A 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.